pioglitazone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 296 Diseases   92 Trials   92 Trials   3449 News 


«12345678910111213...4849»
  • ||||||||||  simvastatin / Generic mfg., pioglitazone / Generic mfg.
    Journal:  Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis. (Pubmed Central) -  Nov 3, 2023   
    Consistent with the above observations, Mito-Esc treatment by activating the AMPK-SIRT1 pathway markedly reversed palmitate-induced mitochondrial superoxide production, depolarization of mitochondrial membrane potential, and lipid accumulation in HepG2 cells. Together, the therapeutic efficacy of Mito-Esc in the mitigation of HFD-induced lipotoxicity, and the associated NASH is in part, mediated by potentiating the AMPK-SIRT1 axis.
  • ||||||||||  pioglitazone / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Preclinical, Journal:  Pioglitazone ameliorates doxorubicin-induced hypothyroidism and cardiotoxicity in rat models. (Pubmed Central) -  Nov 3, 2023   
    PIO co-treatment ameliorated these effects of DOX significantly in FT4, FT3, and troponin I. PIO may provide protection against hypothyroidism and cardiotoxicity caused by DOX treatment, by significant reversal of FT4, FT3, and troponin I levels. https://www.europeanreview.org/wp/wp-content/uploads/Graphical-abstract1.jpg.
  • ||||||||||  pioglitazone / Generic mfg.
    Identification of cell-specific differential gene expression profiles by snRNA-seq following repetitive weaponry-type blast-induced traumatic brain injury (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_11669;    
    agonist, at 30 minutes post-injury...We also conducted gene ontology and pathway analysis to identify functional profiles in various cell types after injury and/or treatment. This study provides a deeper understanding of the mechanisms that underlie neuropathological changes following repetitive weaponry-type blast exposure and provides a foundation for the identification of therapeutic targets that could be modulated to improve the health of Veterans and others with histories of occupational blast exposures.
  • ||||||||||  elafibranor (GFT505) / Ipsen
    Journal:  A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. (Pubmed Central) -  Nov 1, 2023   
    Pioglitazone improved the OOC viability while elafibranor reduced the steatosis in association with reduced viability and albumin production. In conclusion, we show that the HepG2 steatosis OOC model is a useful tool on which the efficacy and toxicity of various therapeutic candidates can be tested.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Pioglitazone-Loaded Cartilage-Targeted Nanomicelles (Pio@C-HA-DOs) for Osteoarthritis Treatment. (Pubmed Central) -  Oct 28, 2023   
    Pio@C-HA-DOs reduced the degradation of collagen II and proteoglycans by inhibiting the expression of MMP and ADAMTS, ultimately delaying OA progression in vitro and in vivo. Herein, C-HA-DOs provided targeted drug delivery to articular cartilage and improved the role of pioglitazone in the treatment of OA.
  • ||||||||||  pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
    Journal:  Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. (Pubmed Central) -  Oct 26, 2023   
    This retrospective cohort study of national VHA data found a relatively low incidence of pancreatitis in both cohorts, and an adjusted odds ratio found no statistical difference of pancreatitis in patients prescribed an incretin therapy compared with a control group. This data adds to growing evidence that incretin therapies do not seem to be associated with an increased risk of developing pancreatitis.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  TRABEPIO: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. (clinicaltrials.gov) -  Oct 26, 2023   
    P2,  N=10, Recruiting, 
    Since the toxicity of impurities is relevant to their structures, toxicology of all five impurities was predicted by three software tools, and the result showed that these compounds have good safety profile. Not yet recruiting --> Recruiting | Trial completion date: Apr 2023 --> Feb 2024 | Trial primary completion date: Apr 2022 --> Feb 2024
  • ||||||||||  pioglitazone / Generic mfg., rosiglitazone / Generic mfg.
    Journal:  Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes. (Pubmed Central) -  Oct 24, 2023   
    Thus, the potential of thiazolidinediones in terms of their chemical evolution, action on nuclear receptors, aldose reductase and free fatty acid receptor 1 is well established. The newer TZD analogues with better safety profiles and tolerability will soon be available in the market for common use without further delay.
  • ||||||||||  rivoglitazone (CS-011) / Daiichi Sankyo, Santen
    Retrospective data, Journal:  Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis. (Pubmed Central) -  Oct 24, 2023   
    Severe adverse events with standard-dose [RR1.88 (95%CI: 0.69-5.12);P = 0.22;I = 0%] and high-dose [RR 1.27 (95% CI: 0.45 - 3.59); P = 0.68; I = 0%] rivoglitazone was comparable to placebo. This meta-analysis highlights the good glycaemic efficacy and safety of both standard and high-dose rivoglitazone, and appears to be better than lobeglitazone in T2DM.
  • ||||||||||  pioglitazone / Generic mfg.
    Trial completion date, Trial primary completion date:  Insulin Regulation of Lipolysis and Lipolysis Proteins (clinicaltrials.gov) -  Oct 23, 2023   
    P1,  N=64, Recruiting, 
    Hence, providing valuable insights into the compressibility behavior of PGZ oral dispersible tablets and also aiding in the development of optimized tablet formulations. Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
  • ||||||||||  Clinical, Retrospective data, Review:  A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS OF MEDICAL THERAPIES FOR LICHEN PLANOPILARIS. (Pubmed Central) -  Oct 18, 2023   
    We propose a triple-combined approach consisting of topical clobetasol, hydroxychloroquine, and N-acetylcysteine as resulted in the most effective approach. Considering the poor outcomes observed with pioglitazone, mycophenolate mofetil, and cyclosporine, it is advisable to contemplate the use of these medications in patients who have not responded adequately to more efficacious alternatives.
  • ||||||||||  Parmodia (pemafibrate) / Kowa
    Review, Journal:  Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. (Pubmed Central) -  Oct 4, 2023   
    Anti-diabetic drugs including metformin, alpha-glucosidase inhibitors, pioglitazone, dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide 1 analogues have been shown to ameliorate postprandial hyperlipidemia...Postprandial hyperlipidemia cannot be specifically defined by measures such as TG levels 2 h after a meal. To study interventions for postprandial hyperlipidemia with the outcome of preventing the onset of ASCVD, it is necessary to define postprandial hyperlipidemia using reference values such as IGT.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal, Machine learning:  Differential effect of interventions in patients with prediabetes (Pubmed Central) -  Oct 2, 2023   
    This study suggests personalized treatment for prediabetes according to their PR is necessary. ML-PR model with simple clinical variables may facilitate personal treatment strategies in participants with prediabetes.
  • ||||||||||  mitoglitazone (MSDC-0160) / Metabolic Solutions
    Review, Journal:  Insulin sensitizers in 2023: lessons learned and new avenues for investigation. (Pubmed Central) -  Sep 27, 2023   
    Pioglitazone remains the best in class with beneficial pleiotropic pharmacology, although use is limited by tolerability issues...Greater understanding of the mechanism of action of insulin sensitizing drugs can expand the rationale for the fields of treatment and potential for treatment combinations. This understanding can facilitate the registration and broader use of agents with that impact the pathophysiology that underlies chronic metabolic diseases as well as host responses to environmental insults including pathogens, insulin sensitizer, MPC, mitochondrial target, metabolic reprogramming, chronic and infectious disease.
  • ||||||||||  resmetirom (MGL-3196) / Madrigal Pharma
    Review, Journal:  NASH Drug Development: Seeing the Light at the End of the Tunnel? (Pubmed Central) -  Sep 18, 2023   
    We compare the efficacy of 33 published clinical trials that evaluated noninvasive biomarkers and liver biopsy. Currently, phase II trial results of fibroblast growth factor 21 (FGF21) and phase III trial results of resmetirom and pioglitazone are encouraging.
  • ||||||||||  tamoxifen / Generic mfg., pioglitazone / Generic mfg.
    Journal:  Eremophila purpurascens: Anti-oxidant, Anti-hyperglycemic, and Hepatoprotective Potential of Its Polyphenolic Rich Leaf Extract and Its LC-ESI-MS/MS Chemical Characterization and Standardization. (Pubmed Central) -  Sep 11, 2023   
    In vitro anti-diabetic evaluation using 3T3-L1 adipocyte culture showed that at a dose of 30 ?g/mL, the EP extract elicited a 6.3% decrease in the concentration of glucose (22.4 mmol/L), showing significant amelioration with regard to pioglitazone and insulin...EP also relieved the liver stress markers both in vitro in CCl and in vivo in tamoxifen (TAM) models...The docking experiment showed that tri-O-galloyl-hexoside had the best fitting within the NADPH oxidase active sites with binding energy (?G = -81.12 kcal/mol). Thus, the plant can be of beneficial value in the control of hyperglycemia in diabetic patients, besides its prophylactic potential against hepatic complications.
  • ||||||||||  pioglitazone / Generic mfg.
    Review, Journal:  Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment. (Pubmed Central) -  Sep 9, 2023   
    Therefore, diabetologists have the opportunity to actively treat NAFLD/MASLD, with a concrete possibility of changing the natural history of the disease. In the present narrative review, we summarize evidence and clinical recommendations for NAFLD/MAFLD screening in the setting of T2D, as well as on the effect of currently available glucose-lowering drugs on hepatic endpoints.